



ASX/Media Release (Code: ASX: ADO)

3 March 2016

ANTEO SECURES US\$6.5M INVESTMENT AGREEMENT WITH US INSTITUTIONAL INVESTOR BERGEN

Highlights

- Investment agreement for up to US\$6.5 million to contribute to Anteo's funding for the earn out component of the acquisition of DIAsource Immunoassays SA and provide ongoing working capital
- Potentially avoids share value dilution at current levels
- Inbuilt flexibility and competitive terms

Anteo Diagnostics Limited (ASX: ADO) ("**Anteo**" or the "**Company**") is pleased to announce the execution of an investment agreement (the "**Agreement**") with Bergen Global Opportunity Fund, LP ("**Bergen**" or the "**Investor**"), a New York institutional investor managed by Bergen Asset Management, LLC ("**Bergen Asset Management**").

Under the Agreement, Bergen will make an initial upfront investment of US\$1.5 million immediately and US\$0.5 million in 120 days, each by way of an interest-free unsecured convertible security with a 24 month maturity. Bergen may also invest up to a further US\$4.5 million in Anteo's equity over the next 24 months by mutual consent of Bergen and the Company.

This investment will contribute to Anteo's funding for the earn out component of the acquisition of DIAsource Immunoassays SA ("**DIAsource**"), that has been announced previously, as well as ongoing working capital. The working capital will principally be used for continuation of Anteo's research and development activities in diagnostics, energy and medical devices.

Importantly, Anteo has retained the right to agree to further investments and there is no obligation to draw the facility beyond the first 2 tranches. Additionally, Anteo has the right to terminate the Agreement at any time. Bergen has also agreed to certain, strict limitations on exiting its investment. The key aspects of the Agreement and the Company's rationale for securing this funding are set out in the Appendix below.

Anteo's Chief Executive Officer, Dr Geoff Cumming said: "The funding provides us with financing to contribute to the earn out payments for the acquisition of DIAsource and working capital required over the next two years as we continue to develop our commercialisation program for diagnostics, energy storage and medical devices. This investment structure



anteo diagnostics

potentially reduces dilution for our shareholders at today's subdued level while allowing us to maintain a substantial and relatively constant cash balance."

Mr. Eugene Tablis, Bergen Asset Management's Chief Investment Officer commented: "We look forward to working with Anteo as it executes on its corporate and scientific plans. Our best investments have been made in companies in transition, and we have had great experiences with Australian healthcare and biotech investments. We are delighted to be able to provide the company with funding to assist in the acquisition and for the continued commercialisation of its platform technology."

About Anteo Diagnostics Limited

Anteo Diagnostics Limited (ASX: ADO) is a global medical technology company, developing and commercialising products for sale into the life sciences, in-vitro diagnostics, point of care, medical devices and bioseparations markets. The Anteo group owns a patented nanoglue technology, which is used by healthcare customers for incorporation into their existing tests and tests under development, to consistently enable laboratory test results that can either be delivered faster, cheaper, or with greater specificity or sensitivity than incumbent tests. This nanoglue technology, called Mix&Go for healthcare markets, is starting to gain traction with the Company's target markets, due to its ability to revolutionise the way scientists work. While Anteo is largely focused on the healthcare markets, the nanoglue technology also has potential for use in other areas, such as batteries. Early stage research is being conducted into the viability of this battery product. For more information, please visit www.anteodx.com

About Bergen Asset Management

Based in New York, Bergen Asset Management is an institutional investor with a particular focus on direct investments in small-cap companies around the world, and a track record of success in the Australian biotech market.



APPENDIX

1. **Certainty of access to funding.** The Agreement provides the Company with certainty of access to funding in a tight capital market environment over the next 24 months. The investment will be made as follows:
 - A. US\$1,500,000 invested on execution of the Agreement by way of an interest-free unsecured convertible security with 24-month maturity (the “**Convertible**”); and
 - B. an additional US\$500,000 invested 120 days after execution of the Agreement by way of an interest-free unsecured convertible security with 24-month maturity; and
 - C. up to a further US\$4,500,000 invested by mutual agreement under a 24-month interest-free unsecured convertible security facility,for a total of up to US\$6,500,000 (the “**Total**”).
2. **Minimizing dilution.** Bergen will purchase convertible notes in the Company. The conversion price of the convertible notes will be the lesser of 92% of the average of five daily volume-weighted average prices (“**VWAPs**”) of the Company’s shares during a specified period immediately prior to the date of the issuance of the ordinary shares or 140% of the average of daily VWAPs for 20 trading days prior to the date of execution of the Agreement.

This allows the Company to potentially issue new shares at prices that are linked to the prices prevailing at the time of the conversion (i.e. potentially at a premium to the current share price) and minimise the dilution for its shareholders.
3. **Additional safeguards for the Company.** The Company has a number of additional safeguards, with a particular focus on safeguards against dilution. These include the following:
 - A. The Company can opt not to issue further tranches, and terminate the Agreement without penalty. This ensures that the Company can avoid dilution at below a level that is acceptable to it.
 - B. With US\$1,500,000 advanced on execution, an additional US\$500,000 firmly committed, and additional US\$4,500,000 available by mutual consent, the Company has avoided dilution at today’s historically low levels, while retaining substantial flexibility.



- C. The Company may easily terminate the Agreement thus avoiding the need for further tranches all together, if its developments would result in a better funding option being available elsewhere or if funding was no longer required all together.
 - D. Bergen has agreed to certain, strict limitations on a sale of its investment, a safeguard which would not be available in a multi-investor placement.
 - E. The investment is not subject to any financial ratio covenants other than the Company securing it against 7.5 million collateral shares.
 - F. Bergen is a passive financial investor with no board participation rights.
- 4. Interest-free investment and focus on capital appreciation.** Bergen's return on investment depends on the Company's share price appreciation and, consequently, its investment accrues no interest.
- 5. Options priced at a premium.** Bergen will be granted 9.8 million options with a term of 3 years to acquire ordinary shares in the Company at an exercise price of 130% of the average of the VWAPs of the Company's shares for the 20 trading days immediately prior to the date of the agreement, which maximises Bergen's interests in the Company's share price appreciation.
- 6. Further Funding.** The Agreement does not restrict the Company from raising additional funding.
- 7. Other.** Bergen will receive a commencement fee in connection with its investment in the Company, to be satisfied by way of issuance of 4,649,156 shares in the Company.

The terms of the Agreement require Anteo to use its capacity under Listing Rule 7.1 and 7.1A, to issue the equity securities referred to above.